Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325748 · ClinicalTrials.gov registry record · Phase 1
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
A Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies, sponsored by Senti Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 8
- Study locations
NCT06325748 is a Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies that is active but no longer recruiting, run by Senti Biosciences. The registered enrollment target is 21 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT06325748, a Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies, is active but no longer recruiting, sponsored by Senti Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Conditions Studied
Interventions
- BIOLOGICAL SENTI-202
Study Locations (8)
Texas
- MD Anderson Cancer Center - Houston
- Methodist Healthcare - San Antonio
California
- UCLA Medical Center - Los Angeles
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic - Jacksonville
Tennessee
- TriStar Bone Marrow Transplant - Nashville
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Victoria
- Peter MacCallum Cancer Center - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2040-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06325748
The ClinicalTrials.gov registry entry for NCT06325748 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senti Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with AML/MDS appearing as the primary indexed condition, and to 1 intervention - of which SENTI-202 is the first listed.
NCT06325748 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06325748 about?
NCT06325748 is a clinical study titled "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS". This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
What is the current status of trial NCT06325748?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-04-22. Estimated completion is 2040-08.
What conditions does trial NCT06325748 study?
This clinical trial studies the following conditions: AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies.
What interventions are being tested in trial NCT06325748?
The interventions under investigation include: SENTI-202 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06325748?
This trial is sponsored by Senti Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06325748 being conducted?
This trial has 8 study locations across California, Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML/MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.